Year-end Sale % OFF 
Abstract
BackgroundMortality among patients with tuberculosis (TB)/HIV is highest during the first few months of antituberculous therapy. The objective of this study was to assess the factors associated with early mortality among TB/HIV patients and whether these factors are similar for HAART naïve and those with prior HAART initiation.MethodsProspective cohort study including HIV patients with tuberculosis confirmed by culture, cared for at a referral center in Rio de Janeiro, Brazil. Multivariable Cox analysis was used to assess predictors of mortality within 3 months of antituberculous therapy.ResultsAmong 227 patients included, 90 (40%) started HAART before TB diagnosis. The median time to TB diagnosis after ARV initiation was 5.9 months (interquartile range [IQR] 3.0–8.9 months). Fourteen patients (6%) died within the first 3 months. Mortality was not different between patients previously started on HAART and those who were naïve to it. In the overall adjusted analysis, HAART use during TB treatment (hazard ratio [HR] = 0.21, 95% confidential interval [CI] = 0.06–0.72) and CD4 lymphocyte count >100 cells/mm3 (HR = 0.21, 95% CI = 0.04–0.99) were associated with lower mortality, while subjects with unknown baseline CD4 lymphocyte count (HR = 9.39, 95% CI = 2.56–34.5) had higher mortality. In subgroup analysis, among HAART naïve subjects, disseminated TB (HR = 5.32, 95% CI = 1.09–25.8) and unknown baseline CD4 lymphocyte count (HR = 13.2, 95% CI = 2.71–64.5) were associated with significantly higher mortality, while HAART (HR = 0.14, 95% CI = 0.03–0.69) predicted a better outcome. Among subjects previously started on HAART, mortality was significantly associated with duration of TB symptoms >120 days (HR = 6.15, 95% CI = 1.15–32.9).ConclusionsPredictors of early mortality among TB/HIV patients may vary according to the timing of HAART initiation. Among HAART naïve patients, mortality was influenced by baseline clinical severity, HAART use and, possibly, the quality of care preceding TB diagnosis. For patients with prior HAART initiation, longer delays in TB diagnosis predicted a significantly higher mortality.
Highlights
Tuberculosis (TB) is an important cause of death worldwide, especially in resource-limited countries, where the intersection with HIV pandemics has led to a marked increase in its prevalence
In countries where antiretroviral therapy has been widely available for a long time, such as in Brazil, there is an increasing proportion of HIV patients who start antituberculous therapy already on HAART [12] and it is plausible that factors influencing early mortality among them may not be the same as observed among HAART naıve subjects
Among 402 TB/HIV patients that started antituberculous treatment during the analyzed period, 227 subjects (56.5%) with a diagnosis of M. tuberculosis infection confirmed by culture were included in the study (Figure 1)
Summary
Tuberculosis (TB) is an important cause of death worldwide, especially in resource-limited countries, where the intersection with HIV pandemics has led to a marked increase in its prevalence. Among TB/HIV patients who start antituberculous therapy, the mortality rate is highest within the first three months after the diagnosis of TB [3,4,5,6]. To our knowledge, no study has assessed the predictors of early mortality among HIV subjects who recently started antituberculous therapy. In countries where antiretroviral therapy has been widely available for a long time, such as in Brazil, there is an increasing proportion of HIV patients who start antituberculous therapy already on HAART [12] and it is plausible that factors influencing early mortality among them may not be the same as observed among HAART naıve subjects. The objective of this study was to assess the factors associated with early mortality among TB/HIV patients and whether these factors are similar for HAART naıve and those with prior HAART initiation
Sign-in/Register to view highlights & summary Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
